patient subgroup...
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
anti-inflammatoty and immuno-therapy - versus potential COVID-19 treatments - for COVID 19 hospitalized
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.89 [0.83, 0.95]< 1 38% 85 studies (84/1) 100.0 % moderate critical moderate crucial - death or transfer to ICU 0.83 [0.65, 1.06]< 1 46% 7 studies (5/2) 92.9 % low not evaluable high crucial - deaths 0.72 [0.64, 0.82]< 1 94% 175 studies (141/34) 100.0 % moderate critical moderate crucial 1 deaths (time to event analysis only) 0.74 [0.53, 1.03]< 1 95% 34 studies (27/7) 96.2 % moderate critical moderate crucial - clinical deterioration 0.75 [0.61, 0.93]< 1 63% 32 studies (29/3) 99.5 % moderate low moderate important - clinical improvement 1.21 [1.11, 1.32]> 1 45% 40 studies (39/1) 100.0 % moderate critical moderate important - clinical improvement (14-day) 1.37 [1.15, 1.64]> 1 40% 14 studies (14/-) 100.0 % some concern critical moderate important - clinical improvement (21-day) 1.50 [0.22, 10.08]> 1 0% 1 study (1/-) 66.1 % NA not evaluable important - clinical improvement (28-day) 1.70 [1.22, 2.38]> 1 52% 13 studies (12/1) 99.9 % moderate critical moderate important - clinical improvement (7-day) 1.46 [0.99, 2.14]> 1 51% 8 studies (8/-) 97.2 % some concern serious moderate important - clinical improvement (time to event analysis only) 1.12 [1.04, 1.22]> 1 15% 20 studies (20/-) 99.8 % some concern critical moderate important - death or ventilation 0.91 [0.86, 0.96]< 1 52% 30 studies (30/-) 100.0 % some concern critical moderate important - hospital discharge 1.16 [1.05, 1.28]> 1 82% 20 studies (17/3) 99.9 % moderate critical moderate important - hospitalization 1.00 [0.14, 7.34]< 1 0% 1 study (1/-) 50.0 % NA not evaluable important - mechanical ventilation 0.86 [0.78, 0.94]< 1 26% 39 studies (37/2) 99.9 % moderate critical moderate important 1 mechanical ventilation (time to event analysis only) 0.97 [0.62, 1.52]< 1 0% 2 studies (2/-) 55.5 % some concern not evaluable moderate important - radiologic improvement (14-day) 3.49 [2.17, 5.60]> 1 0% 5 studies (5/-) 100.0 % some concern not evaluable moderate important - Recovery (time to event analysis only) 1.02 [0.81, 1.28]> 1 0% 1 study (1/-) 56.7 % NA not evaluable important - viral clearance 2.60 [1.42, 4.73]> 1 79% 11 studies (11/-) 99.9 % some concern critical moderate important - viral clearance (time to event analysis only) 1.60 [0.92, 2.79]> 1 79% 4 studies (4/-) 95.2 % some concern not evaluable moderate important - viral clearance by day 14 1.38 [0.20, 9.41]> 1 96% 7 studies (7/-) 62.9 % some concern not evaluable moderate important - viral clearance by day 7 1.57 [1.13, 2.18]> 1 58% 9 studies (9/-) 99.6 % some concern serious moderate important - ICU admission 0.65 [0.48, 0.88]< 1 59% 21 studies (16/5) 99.7 % moderate critical moderate non important - off oxygenation 1.65 [0.05, 50.02]> 1 81% 2 studies (2/-) 61.1 % high not evaluable low non important - recovery 1.17 [0.98, 1.39]> 1 25% 7 studies (7/-) 96.2 % low not evaluable high non important - 00 composite safety outcome 1.56 [0.78, 3.11]< 1 0% 1 study (1/-) 10.3 % NA not evaluable important - related AE (TRAE) 1.26 [0.14, 11.07]< 1 0% 2 studies (2/-) 41.9 % some concern not evaluable moderate important - related SAE (TRSAE) 2.04 [0.07, 63.93]< 1 0% 1 study (1/-) 34.4 % NA not evaluable important - serious adverse events 1.04 [0.90, 1.20]< 1 19% 29 studies (29/-) 28.4 % some concern low moderate important - superinfection 1.04 [0.57, 1.90]< 1 80% 6 studies (5/1) 45.3 % moderate not evaluable moderate important - acute kidney injury 0.43 [0.14, 1.34]< 1 0% 1 study (-/1) 92.7 % NA not evaluable non important - adverse events 1.22 [0.97, 1.53]< 1 44% 25 studies (25/-) 4.7 % some concern low moderate non important - arrhythmia 0.16 [0.03, 0.90]< 1 0% 1 study (-/1) 98.1 % NA not evaluable non important - cardiovascular or renal events 1.87 [1.25, 2.80]< 1 0% 1 study (-/1) 0.1 % NA not evaluable non important - elevated liver enzymes 0.52 [0.18, 1.51]< 1 0% 1 study (-/1) 88.5 % NA not evaluable non important - Myocardial infarction 0.87 [0.19, 3.92]< 1 0% 1 study (-/1) 57.2 % NA not evaluable non important - venous thromboembolism 5.23 [0.42, 65.62]< 1 0% 1 study (-/1) 10.2 % NA not evaluable non important -
LoD: level of statistical demonstration:
